Drug General Information
Drug ID
D07VIB
Former ID
DNCL001894
Drug Name
Tecarfarin
Synonyms
ATI-5923
Drug Type
Small molecular drug
Indication Cerebrovascular ischaemia [ICD9: 434.91; ICD10:I61-I63] Phase 3 [525289]
Company
ARYx Therapeutics
Structure
Download
2D MOL

3D MOL

Formula
C21H14F6O5
Canonical SMILES
CC(C(F)(F)F)(C(F)(F)F)OC(=O)C1=CC=C(C=C1)CC2=C(C3=CC=CC<br />=C3OC2=O)O
InChI
1S/C21H14F6O5/c1-19(20(22,23)24,21(25,26)27)32-17(29)12-8-6-11(7-9-12)10-14-16(28)13-4-2-3-5-15(13)31-18(14)30/h2-9,28H,10H2,1H3
InChIKey
QFLNTQDOVCLQKW-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Vitamin K epoxide reductase complex subunit 1 Target Info Inhibitor [531029]
KEGG Pathway Ubiquinone and other terpenoid-quinone biosynthesis
PathWhiz Pathway Vitamin K Metabolism
Coagulation
WikiPathways PTM: gamma carboxylation, hypusine formation and arylsulfatase activation
References
Ref 525289ClinicalTrials.gov (NCT02522221) Tecarfarin Anti-Coagulation Trial (TACT).
Ref 531029Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011Apr;51(4):561-74.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.